Table 3. Patients and clinical feature of HSIL− vs. HSIL+.
Clinical features | Training set | Testing set | |||||
---|---|---|---|---|---|---|---|
HSIL− (n=3,758) | HSIL+ (n=1,513) | P | HSIL− (n=1,082) | HSIL+ (n=424) | P | ||
Age | 0.014 | 0.331 | |||||
Mean | 40.6 | 39.9 | 40.2 | 40.8 | |||
Range | 16–75 | 15–79 | 18–77 | 21–79 | |||
Cytology | *** | *** | |||||
Negative | 3,079 | 707 | 878 | 202 | |||
Positive | 679 | 806 | 204 | 222 | |||
HPV | *** | *** | |||||
Negative | 357 | 24 | 101 | 3 | |||
Positive | 3,401 | 1,489 | 981 | 421 | |||
Gravidity | 0.001 | 0.038 | |||||
≤2 | 1,764 | 634 | 503 | 172 | |||
>2 | 1,994 | 879 | 579 | 252 | |||
Parity | 0.362 | 0.162 | |||||
≤2 | 3,579 | 1,432 | 1,030 | 396 | |||
>2 | 179 | 81 | 52 | 28 | |||
Contraception | 0.383 | 0.504 | |||||
Condom | 1,262 | 489 | 366 | 135 | |||
No condom | 2,496 | 1,024 | 716 | 289 |
***, P<0.001. HSIL, high-grade squamous intraepithelial lesions; HPV, human papillomavirus.